Respiratory Syncytial Virus (RSV) vaccine (bivalent, recombinant) powder and solvent for solution for injection 0.5ml vials
NHS hospitals in England used £36,275,852 of indicative cost of Respiratory Syncytial Virus (RSV) vaccine (bivalent, recombinant) powder and solvent for solution for injection 0.5ml vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 19.0% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Respiratory Syncytial Virus (RSV) vaccine (bivalent, recombinant) powder and solvent for solution for injection 0.5ml vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Respiratory Syncytial Virus (RSV) vaccine (bivalent, recombinant) powder and solvent for solution for injection 0.5ml vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Manchester University Nhs Ft | £1,275,692 |
| Barts Health Nhs Trust | £1,106,000 |
| Chelsea & Westminster Hospital Nhs Ft | £1,083,248 |
| Western Sussex Hospitals Nhs Found Trust | £918,454 |
| Royal Free London Nhs Foundation Trust | £731,856 |
| King's College Hpl Nhs Foundation Trust | £677,820 |
| University College London Foundation Tr | £604,666 |
| Portsmouth Hospitals Nhs Trust | £591,394 |
| Lewisham And Greenwich Nhs Trust | £571,012 |
| Imperial College Healthcare Nhs Trust | £561,216 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.